GGrantIndex
← Search

PHASE III CYCLIC TILUDRONATE--POSTMENOPAUSAL OSTEOPOROSI

$0M01FY2000RRNIH

Beth Israel Deaconess Medical Center, Boston MA

Investigators

Linked publications & trials

Abstract

Part I is designed to evaluate the effect of tiludronate on the vertebral fracture rate of postmenopausal women with established osteoporosis and low bone mass by measuring the incidence of vertebral fracture events after two years of treatment. Part II is designed to evaluate the effect of tiludronate on bone mineral density of postmenopausal women with low bone mass and no vertebral fractures.

View original record on NIH RePORTER →